First-trimester proteomic profiling identifies novel predictors of gestational diabetes mellitus.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
07
2018
accepted:
13
03
2019
entrez:
28
3
2019
pubmed:
28
3
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Gestational diabetes mellitus (GDM) is a common pregnancy complication associated with adverse outcomes including preeclampsia, caesarean section, macrosomia, neonatal morbidity and future development of type 2 diabetes in both mother and child. Current selective screening strategies rely on clinical risk factors such as age, family history of diabetes, macrosomia or GDM in a previous pregnancy, and they possess a relatively low specificity. Here we hypothesize that novel first trimester protein predictors of GDM can contribute to the current selective screening strategies for early and accurate prediction of GDM, thus allowing for timely interventions. A proteomics discovery approach was applied to first trimester sera from obese (BMI ≥27 kg/m2) women (n = 60) in a nested case-control study design, utilizing tandem mass tag labelling and tandem mass spectrometry. A subset of the identified protein markers was further validated in a second set of serum samples (n = 210) and evaluated for their contribution as predictors of GDM in relation to the maternal risk factors, by use of logistic regression and receiver operating characteristic analysis. Serum proteomic profiling identified 25 proteins with significantly different levels between cases and controls. Three proteins; afamin, serum amyloid P-component and vitronectin could be further confirmed as predictors of GDM in a validation set. Vitronectin was shown to contribute significantly to the predictive power of the maternal risk factors, indicating it as a novel independent predictor of GDM. Current selective screening strategies can potentially be improved by addition of protein predictors.
Sections du résumé
BACKGROUND
Gestational diabetes mellitus (GDM) is a common pregnancy complication associated with adverse outcomes including preeclampsia, caesarean section, macrosomia, neonatal morbidity and future development of type 2 diabetes in both mother and child. Current selective screening strategies rely on clinical risk factors such as age, family history of diabetes, macrosomia or GDM in a previous pregnancy, and they possess a relatively low specificity. Here we hypothesize that novel first trimester protein predictors of GDM can contribute to the current selective screening strategies for early and accurate prediction of GDM, thus allowing for timely interventions.
METHODS
A proteomics discovery approach was applied to first trimester sera from obese (BMI ≥27 kg/m2) women (n = 60) in a nested case-control study design, utilizing tandem mass tag labelling and tandem mass spectrometry. A subset of the identified protein markers was further validated in a second set of serum samples (n = 210) and evaluated for their contribution as predictors of GDM in relation to the maternal risk factors, by use of logistic regression and receiver operating characteristic analysis.
RESULTS
Serum proteomic profiling identified 25 proteins with significantly different levels between cases and controls. Three proteins; afamin, serum amyloid P-component and vitronectin could be further confirmed as predictors of GDM in a validation set. Vitronectin was shown to contribute significantly to the predictive power of the maternal risk factors, indicating it as a novel independent predictor of GDM.
CONCLUSIONS
Current selective screening strategies can potentially be improved by addition of protein predictors.
Identifiants
pubmed: 30917176
doi: 10.1371/journal.pone.0214457
pii: PONE-D-18-20410
pmc: PMC6436752
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0214457Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Med. 2017 Aug 28;15(1):163
pubmed: 28844206
J Obstet Gynaecol Res. 2012 Nov;38(11):1286-93
pubmed: 22612716
Eur J Obstet Gynecol Reprod Biol. 2016 Jun;201:192-6
pubmed: 27105781
Diabetes Care. 2002 Oct;25(10):1862-8
pubmed: 12351492
Am J Obstet Gynecol. 2003 Jul;189(1):171-6
pubmed: 12861158
Mol Cell Proteomics. 2008 May;7(5):971-80
pubmed: 18212344
Diabetes Care. 2010 Mar;33(3):676-82
pubmed: 20190296
Diabetes. 1991 Dec;40 Suppl 2:8-13
pubmed: 1748272
Diabetes Care. 2018 Jul;41(7):1339-1342
pubmed: 29559508
J Matern Fetal Neonatal Med. 2015;28(14):1720-4
pubmed: 25228278
Clin Chim Acta. 2018 Jan;476:160-166
pubmed: 29191735
Clin Chem Lab Med. 2016 Mar;54(3):509-18
pubmed: 26351946
Clin Chem. 2013 Sep;59(9):1310-21
pubmed: 23536513
Am J Obstet Gynecol. 2007 Apr;196(4):410.e1-6; discussion 410.e6-7
pubmed: 17403439
Diabetes Care. 2007 Aug;30(8):2070-6
pubmed: 17416786
Paediatr Perinat Epidemiol. 2004 Sep;18(5):377-84
pubmed: 15367325
Expert Rev Proteomics. 2017 Mar;14(3):269-276
pubmed: 28222616
N Engl J Med. 2008 May 8;358(19):1991-2002
pubmed: 18463375
Diabetes. 2010 Dec;59(12):3017-22
pubmed: 20876721
Diabetologia. 2016 Apr;59(4):692-9
pubmed: 26768001
Prenat Diagn. 2011 Feb;31(2):135-41
pubmed: 21268030
Diabetologia. 2016 May;59(5):970-9
pubmed: 26818149
Arch Gynecol Obstet. 2015 Jul;292(1):53-8
pubmed: 25527349
Mol Cell Proteomics. 2014 Jan;13(1):311-28
pubmed: 24173317
Am J Obstet Gynecol. 2004 Dec;191(6):2120-4
pubmed: 15592301
Curr Diab Rep. 2017 Feb;17(2):12
pubmed: 28229385
Proteomics Clin Appl. 2017 Jul;11(7-8):
pubmed: 28220636
Diabetes Care. 2013 Jun;36(6):1577-83
pubmed: 23300287
Diabet Med. 2003 Jan;20(1):51-7
pubmed: 12519320
Am J Obstet Gynecol. 2003 Nov;189(5):1383-8
pubmed: 14634573
Acta Diabetol. 2008 Sep;45(3):157-65
pubmed: 18496643
Proteomics Clin Appl. 2015 Aug;9(7-8):767-75
pubmed: 25331251
BMJ. 2016 Aug 30;354:i4338
pubmed: 27576867
J Matern Fetal Neonatal Med. 2014 Jul;27(11):1108-12
pubmed: 24090161
Placenta. 2018 Feb;62:9-15
pubmed: 29405972
Medicine (Baltimore). 2018 Sep;97(36):e12232
pubmed: 30200149